Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mRNA-1647 vaccine for prevention of primary CMV infection in healthy women at risk of exposure to young children
jRCT2031220459Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing mRNA-1647 with Placebo (2 arms). Primary endpoints: Seroconversion from negative to positive serum IgG against antigens not encoded by mRNA-1647, Solicited adverse reactions and 7 more. Started Jan 2023; status: completed.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT2031220459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220459.